Siti Zuhroh

Siti Zuhroh

Auto-generated profile, based on publicly available information

Siti Zuhroh


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
HNHanny Nilasari
Hanny Nilasari
EMEliza Miranda
Eliza Miranda
MMMelani Marissa
Melani Marissa
ARAni Ruspitawati
Ani Ruspitawati
DHDwi O. T. L. Handayani
Dwi O. T. L. Handayani
EYEvy Yunihastuti
Evy Yunihastuti
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.

22 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HNHanny Nilasari
Hanny Nilasari
EMEliza Miranda
Eliza Miranda
MMMelani Marissa
Melani Marissa
ARAni Ruspitawati
Ani Ruspitawati
DHDwi O.T.L. Handayani
Dwi O.T.L. Handayani
EYEvy Yunihastuti
Evy Yunihastuti
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.